Developer docs
API playgroundTry for free, no card

Search company profiles

HighlightLL Pharma

Full company profile

uuid0002qk9

Namestring
HighlightLL Pharma
Legal namestring
杭州高光制药股份有限公司
Company typeenum
Private
Founded yearint
2021
Descriptiontext

HighlightLL Pharma (legal name: 杭州高光制药股份有限公司) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Hangzhou, China (Hangzhou Medical Port, Qiantang District). The company focuses on developing breakthrough small-molecule therapies for autoimmune and inflammatory diseases affecting both the peripheral and central nervous systems. It operates two distinct molecular platforms: a dual TYK2/JAK1 inhibitor platform, headlined by TLL-018 (吉诺昔替尼), the globally first peripheral-selective dual TYK2/JAK1 inhibitor currently in Phase III for chronic spontaneous urticaria and rheumatoid arthritis, and TLL-041 (BHV-8000), the globally first brain-penetrating TYK2/JAK1 inhibitor whose overseas rights were out-licensed to Biohaven in 2023 and which entered a global Phase II/III pivotal Parkinson's trial in May 2025; and an NLRP3 inflammasome inhibitor platform, with HL-400 (brain-penetrating, US Phase I completed April 2026) targeting neurodegenerative diseases and HL-450 targeting peripheral indications. Target patient populations include individuals with chronic spontaneous urticaria, rheumatoid arthritis, Parkinson's disease, and broader neurodegenerative conditions, where current therapies leave substantial unmet medical need.

The company's business model is that of a pre-revenue clinical-stage biopharma. Near-term monetization comes from licensing and co-development partnerships rather than direct product sales — most notably the 2023 Biohaven agreement for TLL-041 overseas rights — with future revenue expected from milestone payments, royalties, and eventually traditional pharmaceutical commercialization through prescription drug distribution channels upon regulatory approval. The go-to-market motion is therefore enterprise-style: partnership-driven global development for international assets and independent domestic development for the China-anchored pipeline. Headcount is small (11–50 employees), there is no commercial sales force, and pricing is not yet applicable to clinical-stage assets. Across two disclosed funding rounds (a ~$30.9M Series A in July 2021 led by AstraZeneca CICC Medical Industry Fund alongside Hankang Capital, Kaitai Capital, Yifeng Capital, and Zeyue Capital; and a ~$20.5M Series B in January 2025 led by Hankang Capital with Huajin Capital, Infinity Equity, and Kangjun Capital), the company has raised approximately $51.4M in total disclosed capital to fund late-stage clinical development and pipeline expansion.

Short descriptiontext

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting peripheral and central nervous systems, with lead assets TLL-018 in Phase III and TLL-041 partnered with Biohaven.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, TYK2/JAK1 inhibitors, NLRP3 inhibitors, autoimmune disease therapeutics, inflammatory disease drugs
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharma. Revenue generation expected through licensing deals, co-development partnerships, and eventual product commercialization. The company has already secured an overseas licensing deal with Biohaven for TLL-041.

highlightpharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting the peripheral and central nervous systems. Its lead asset TLL-018 (ginnoxinib) is in Phase III trials for chronic spontaneous urticaria and rheumatoid arthritis, while TLL-041 (BHV-8000), a brain-penetrant TYK2/JAK1 inhibitor, has been out-licensed to Biohaven for Parkinson's disease. The company also operates an NLRP3 inhibitor platform with HL-400 (CNS) and HL-450 (peripheral).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • TLL-018 achieved positive topline data in rheumatoid arthritis Phase III clinical trial (April 2026)
+3 more records
Product overview1 text field

HighlightLL Pharma is a clinical-stage biopharma company developing breakthrough medicines for autoimmune/inflammatory diseases in peripheral and central nervous systems. The company operates two main platforms: a TYK2/JAK1 inhibitor platform (featuring TLL-018 for peripheral applications in CSU and RA, and TLL-041/BHV-8000 for brain-penetrating neurological applications) and an NLRP3 inhibitor platform (with HL-400 for neurodegenerative diseases and HL-450 for peripheral diseases). The TLL-018 and TLL-041 represent the world's first highly selective dual TYK2/JAK1 inhibitors, with TLL-041 being specifically designed for brain penetration.

Product and service4 records
1TLL-018 (ginnoxinib/吉诺昔替尼)
CategoryTYK2/JAK1 dual inhibitor (autoimmune/inflammatory disease)
Description

The world's first peripheral-selective, highly selective dual TYK2/JAK1 inhibitor. Currently in Phase III clinical development for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA); intended as a prescription therapy for adult patients with these autoimmune/inflammatory conditions who have inadequate response to existing treatments.

2TLL-041 / BHV-8000
CategoryBrain-penetrant TYK2/JAK1 dual inhibitor (CNS/neurodegenerative disease)
Description

The world's first brain-penetrating TYK2/JAK1 inhibitor. Out-licensed to Biohaven in 2023 for overseas development and commercialization; being advanced by Biohaven in a global Phase II/III pivotal clinical trial for Parkinson's disease. Designed to address neuro-inflammation underlying CNS indications.

3HL-400
CategoryNLRP3 inflammasome inhibitor (neurodegenerative disease)
Description

Brain-penetrating NLRP3 inflammasome inhibitor being developed for neurodegenerative diseases. US Phase I clinical trial completed; intended as a prescription therapy targeting neuroinflammation in CNS disorders.

4HL-450
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

HighlightLL Pharma out-licensed overseas rights for TLL-041 (BHV-8000) to Biohaven in 2023. Biohaven advanced the brain-penetrating TYK2/JAK1 inhibitor to Parkinson's disease global Phase II/III pivotal clinical trial in May 2025. This represents a major strategic partnership for international development and commercialization of the company's brain-penetrating CNS asset.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis acquired IFM Tre to build an NLRP3 inhibitor pipeline, directly competing with HighlightLL's NLRP3 platform. As a broad incumbent, Novartis brings substantially greater scale and commercialization capability to the same mechanistic space.

TypeDirect peer
Description

Incyte is the originator of ruxolitinib (Jakavi, JAK1/2) and continues to develop next-generation JAK inhibitors. As a JAK-class pioneer, Incyte is a comparable peer in the autoimmune/inflammatory small-molecule space targeted by HighlightLL.

TypeDirect peer
Description

AbbVie markets Rinvoq (upadacitinib), a JAK1 inhibitor approved across multiple autoimmune indications including RA and CSU-adjacent conditions. TLL-018 targets RA and CSU indications where Rinvoq is already an entrenched standard of care.

TypeBroad incumbent
Description

Roche acquired Inflazome in 2020 to access its NLRP3 inhibitor portfolio for inflammatory and CNS diseases. Roche represents a broad incumbent competitor to HighlightLL's NLRP3 franchise (HL-400, HL-450) in both neurodegenerative and peripheral indications.

TypeEmerging player
Description

Kymera is developing targeted protein degraders including a TYK2 degrader program for autoimmune diseases. Its TYK2 modality represents an emerging approach competing for the same autoimmune patient population targeted by TLL-018.

6Bristol-Myers Squibb
TypeDirect peer
Description

BMS developed and commercializes Sotyktu (deucravacitinib), an allosteric TYK2 inhibitor approved in psoriasis and advancing into other autoimmune indications. TLL-018 competes in the same autoimmune TYK2/JAK1 therapeutic space with overlapping patient populations.

TypeEmerging player
Description

NodThera is a clinical-stage biotech developing brain-penetrant and peripheral NLRP3 inhibitors for inflammatory and neurodegenerative diseases. It is the closest direct emerging peer to HighlightLL's HL-400 (brain-penetrant NLRP3) and HL-450 programs.

TypeDirect peer
Description

Pfizer markets Cibinqo (abrocitinib, JAK1) and Litfulo (ritlecitinib, JAK3/TEC) for atopic dermatitis and alopecia areata. Pfizer is also developing TYK2-targeting agents, directly overlapping HighlightLL's TYK2/JAK1 franchise in autoimmune diseases.

TypeEmerging player
Description

Olatec is developing dapansutrile and other NLRP3 inhibitors for inflammatory and metabolic diseases. As an NLRP3-focused emerging player, Olatec competes with HighlightLL's NLRP3 platform in overlapping peripheral inflammatory indications.

TypeDirect peer
Description

Lilly markets Olumiant (baricitinib, JAK1/2) in collaboration with Incyte across RA, atopic dermatitis and alopecia areata. Lilly's JAK franchise directly competes with TLL-018 in RA and adjacent autoimmune indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HighlightLL Pharma

Clinical-stage Biopharmaceuticalshighlightllpharma.com

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting peripheral and central nervous systems, with lead assets TLL-018 in Phase III and TLL-041 partnered with Biohaven.

What HighlightLL Pharma does

HighlightLL Pharma (legal name: 杭州高光制药股份有限公司) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Hangzhou, China (Hangzhou Medical Port, Qiantang District). The company focuses on developing breakthrough small-molecule therapies for autoimmune and inflammatory diseases affecting both the peripheral and central nervous systems. It operates two distinct molecular platforms: a dual TYK2/JAK1 inhibitor platform, headlined by TLL-018 (吉诺昔替尼), the globally first peripheral-selective dual TYK2/JAK1 inhibitor currently in Phase III for chronic spontaneous urticaria and rheumatoid arthritis, and TLL-041 (BHV-8000), the globally first brain-penetrating TYK2/JAK1 inhibitor whose overseas rights were out-licensed to Biohaven in 2023 and which entered a global Phase II/III pivotal Parkinson's trial in May 2025; and an NLRP3 inflammasome inhibitor platform, with HL-400 (brain-penetrating, US Phase I completed April 2026) targeting neurodegenerative diseases and HL-450 targeting peripheral indications. Target patient populations include individuals with chronic spontaneous urticaria, rheumatoid arthritis, Parkinson's disease, and broader neurodegenerative conditions, where current therapies leave substantial unmet medical need.

The company's business model is that of a pre-revenue clinical-stage biopharma. Near-term monetization comes from licensing and co-development partnerships rather than direct product sales — most notably the 2023 Biohaven agreement for TLL-041 overseas rights — with future revenue expected from milestone payments, royalties, and eventually traditional pharmaceutical commercialization through prescription drug distribution channels upon regulatory approval. The go-to-market motion is therefore enterprise-style: partnership-driven global development for international assets and independent domestic development for the China-anchored pipeline. Headcount is small (11–50 employees), there is no commercial sales force, and pricing is not yet applicable to clinical-stage assets. Across two disclosed funding rounds (a ~$30.9M Series A in July 2021 led by AstraZeneca CICC Medical Industry Fund alongside Hankang Capital, Kaitai Capital, Yifeng Capital, and Zeyue Capital; and a ~$20.5M Series B in January 2025 led by Hankang Capital with Huajin Capital, Infinity Equity, and Kangjun Capital), the company has raised approximately $51.4M in total disclosed capital to fund late-stage clinical development and pipeline expansion.

HighlightLL Pharma firmographics

Firmographics
Name
HighlightLL Pharma
Legal name
杭州高光制药股份有限公司
Website
https://highlightllpharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting peripheral and central nervous systems, with lead assets TLL-018 in Phase III and TLL-041 partnered with Biohaven.
Ownership category
akta.pro rank

HighlightLL Pharma industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biopharmaceuticals
  • TYK2/JAK1 inhibitors
  • NLRP3 inhibitors
  • Autoimmune disease therapeutics
  • Inflammatory disease drugs

Where HighlightLL Pharma is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices1 record

Markets served

HighlightLL Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: Pre-revenue clinical-stage biopharma. Revenue generation expected through licensing deals, co-development partnerships, and eventual product commercialization. The company has already secured an overseas licensing deal with Biohaven for TLL-041.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

HighlightLL Pharma product offering

Product offering

Core offering

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting the peripheral and central nervous systems. Its lead asset TLL-018 (ginnoxinib) is in Phase III trials for chronic spontaneous urticaria and rheumatoid arthritis, while TLL-041 (BHV-8000), a brain-penetrant TYK2/JAK1 inhibitor, has been out-licensed to Biohaven for Parkinson's disease. The company also operates an NLRP3 inhibitor platform with HL-400 (CNS) and HL-450 (peripheral).

Product overview

HighlightLL Pharma is a clinical-stage biopharma company developing breakthrough medicines for autoimmune/inflammatory diseases in peripheral and central nervous systems. The company operates two main platforms: a TYK2/JAK1 inhibitor platform (featuring TLL-018 for peripheral applications in CSU and RA, and TLL-041/BHV-8000 for brain-penetrating neurological applications) and an NLRP3 inhibitor platform (with HL-400 for neurodegenerative diseases and HL-450 for peripheral diseases). The TLL-018 and TLL-041 represent the world's first highly selective dual TYK2/JAK1 inhibitors, with TLL-041 being specifically designed for brain penetration.

Differentiator

Problem solved

Functional benefit

Products and services

  • TLL-018 (ginnoxinib/吉诺昔替尼) The world's first peripheral-selective, highly selective dual TYK2/JAK1 inhibitor. Currently in Phase III clinical development for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA); intended as a prescription therapy for adult patients with these autoimmune/inflammatory conditions who have inadequate response to existing treatments.
  • TLL-041 / BHV-8000 The world's first brain-penetrating TYK2/JAK1 inhibitor. Out-licensed to Biohaven in 2023 for overseas development and commercialization; being advanced by Biohaven in a global Phase II/III pivotal clinical trial for Parkinson's disease. Designed to address neuro-inflammation underlying CNS indications.
  • HL-400 Brain-penetrating NLRP3 inflammasome inhibitor being developed for neurodegenerative diseases. US Phase I clinical trial completed; intended as a prescription therapy targeting neuroinflammation in CNS disorders.
  • HL-450

Quantifiable outcome

  • TLL-018 achieved positive topline data in rheumatoid arthritis Phase III clinical trial (April 2026)
  • +3 more outcomes

Companies that use HighlightLL Pharma

Customer profile

Segments4 records

Ideal customer profiles2 records

HighlightLL Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

HighlightLL Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BiohavenflagshipStrategic or Co-development Partner · 1 January 2023HighlightLL Pharma out-licensed overseas rights for TLL-041 (BHV-8000) to Biohaven in 2023. Biohaven advanced the brain-penetrating TYK2/JAK1 inhibitor to Parkinson's disease global Phase II/III pivotal clinical trial in May 2025. This represents a major strategic partnership for international development and commercialization of the company's brain-penetrating CNS asset.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

HighlightLL Pharma competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis acquired IFM Tre to build an NLRP3 inhibitor pipeline, directly competing with HighlightLL's NLRP3 platform. As a broad incumbent, Novartis brings substantially greater scale and commercialization capability to the same mechanistic space.
  • Roche: Roche acquired Inflazome in 2020 to access its NLRP3 inhibitor portfolio for inflammatory and CNS diseases. Roche represents a broad incumbent competitor to HighlightLL's NLRP3 franchise (HL-400, HL-450) in both neurodegenerative and peripheral indications.

Direct peers

  • Incyte: Incyte is the originator of ruxolitinib (Jakavi, JAK1/2) and continues to develop next-generation JAK inhibitors. As a JAK-class pioneer, Incyte is a comparable peer in the autoimmune/inflammatory small-molecule space targeted by HighlightLL.
  • AbbVie: AbbVie markets Rinvoq (upadacitinib), a JAK1 inhibitor approved across multiple autoimmune indications including RA and CSU-adjacent conditions. TLL-018 targets RA and CSU indications where Rinvoq is already an entrenched standard of care.
  • Bristol-Myers Squibb: BMS developed and commercializes Sotyktu (deucravacitinib), an allosteric TYK2 inhibitor approved in psoriasis and advancing into other autoimmune indications. TLL-018 competes in the same autoimmune TYK2/JAK1 therapeutic space with overlapping patient populations.
  • Pfizer: Pfizer markets Cibinqo (abrocitinib, JAK1) and Litfulo (ritlecitinib, JAK3/TEC) for atopic dermatitis and alopecia areata. Pfizer is also developing TYK2-targeting agents, directly overlapping HighlightLL's TYK2/JAK1 franchise in autoimmune diseases.
  • Eli Lilly: Lilly markets Olumiant (baricitinib, JAK1/2) in collaboration with Incyte across RA, atopic dermatitis and alopecia areata. Lilly's JAK franchise directly competes with TLL-018 in RA and adjacent autoimmune indications.

Emerging players

  • Kymera Therapeutics: Kymera is developing targeted protein degraders including a TYK2 degrader program for autoimmune diseases. Its TYK2 modality represents an emerging approach competing for the same autoimmune patient population targeted by TLL-018.
  • NodThera: NodThera is a clinical-stage biotech developing brain-penetrant and peripheral NLRP3 inhibitors for inflammatory and neurodegenerative diseases. It is the closest direct emerging peer to HighlightLL's HL-400 (brain-penetrant NLRP3) and HL-450 programs.
  • Olatec Therapeutics: Olatec is developing dapansutrile and other NLRP3 inhibitors for inflammatory and metabolic diseases. As an NLRP3-focused emerging player, Olatec competes with HighlightLL's NLRP3 platform in overlapping peripheral inflammatory indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

HighlightLL Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HighlightLL Pharma leadership team

Management profile

Number of profiles

HighlightLL Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HighlightLL Pharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HighlightLL Pharma

What does HighlightLL Pharma do?

HighlightLL Pharma is a clinical-stage biopharmaceutical company developing first-in-class dual TYK2/JAK1 inhibitors and NLRP3 inhibitors for autoimmune and inflammatory diseases affecting the peripheral and central nervous systems. Its lead asset TLL-018 (ginnoxinib) is in Phase III trials for chronic spontaneous urticaria and rheumatoid arthritis, while TLL-041 (BHV-8000), a brain-penetrant TYK2/JAK1 inhibitor, has been out-licensed to Biohaven for Parkinson's disease. The company also operates an NLRP3 inhibitor platform with HL-400 (CNS) and HL-450 (peripheral).

Is HighlightLL Pharma a public or private company?

HighlightLL Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was HighlightLL Pharma founded?

HighlightLL Pharma was founded in 2021. It employs 1 to 10 people.

Where is HighlightLL Pharma based?

HighlightLL Pharma is headquartered in Hangzhou, China, in the Asia region.

How does HighlightLL Pharma make money?

One revenue line is on record: drug Development and Licensing.

Who are HighlightLL Pharma's main competitors?

Broad incumbents on record are Novartis and Roche. Direct peers are Incyte, AbbVie, Bristol-Myers Squibb, Pfizer and Eli Lilly. Emerging players are Kymera Therapeutics, NodThera and Olatec Therapeutics.

Does HighlightLL Pharma have an API?

No public API is recorded for HighlightLL Pharma.

What industry is HighlightLL Pharma in?

HighlightLL Pharma's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals